MergerJun 16, 2026, 07:44 PM
Nano Dimension Defends Infinite Epigenetics Merger, Cites 20% Premium
AI Summary
Nano Dimension Ltd. issued a shareholder update to provide additional details and defend its proposed business combination with Infinite Epigenetics, addressing concerns raised by Murchinson. The company highlights Infinite Epigenetics as a real business with proven science in the epigenetics market, an operating diagnostic platform with existing commercial revenue, and a proprietary biological AI platform. Nano Dimension states that the transaction offers shareholders a 20% premium on the company's cash value and represents a strategic shift into the significantly larger AI-powered preventive health and diagnostics market.
Key Highlights
- Nano Dimension defends proposed business combination with Infinite Epigenetics.
- Shareholders are afforded a 20% premium for the cash value of Nano Dimension through ownership in the combined entity.
- Infinite Epigenetics is an operating diagnostic platform with existing commercial revenue and a network of over 7,500 healthcare providers.
- Infinite's proprietary database comprises more than 120,000 biological samples.
- The transaction shifts Nano Dimension's operations from 3D printing to AI-powered preventive health and diagnostics.
- The chronic disease diagnostics market, which Infinite operates in, exceeds $90 billion.
- Nano Dimension's capital will fund acceleration of Infinite's commercialization and expansion of its proprietary methylation dataset and AI platform.
- The Board emphasizes alignment with shareholder interests and rejects Murchinson's implications.
Price Impact
More from NNDM